Clinical trials: Skin Toxicity
Breast Cancer, Cardiac Toxicity
CADY Study ICORG 08-01
RATIONALE: Studying samples of blood in the laboratory from patients with cancer treated with trastuzumab may help doctors learn more about biomarkers related to heart dysfunction.
- Trial name
- NCT00968682
- Testing
- trastuzumab, laboratory biomarker analysis, assessment of therapy complications
- Where
- 14 sites in Ireland
- Volunteers
- 480 people
- Sponsor
- Cancer Trials Ireland
Psoriasis Chronic, Injury of Liver
Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis
Methotrexate (MTX) is widely prescribed to treat inflammatory conditions including psoriasis, where it is the recommended first-line systemic therapy in moderate-to-severe disease.
- Trial name
- MTXPG (NCT02174354)
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- King's College London
Breast Cancer, Surgery
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer.
- Conditions
- Breast Cancer, Surgery, Adjuvant Radiotherapy
- Trial name
- NCT04913532
- Testing
- Hypofractionation with simultaneous integrated boost
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Capital Medical University
Breast Cancer
Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique
In summary, breast conserving therapy (BCT) is an effective, save and widely used treatment technique for early breast cancer. Radiotherapy has shown to give better local control and survival benefit and is an integrated part of…
- Trial name
- FUSIB (NCT02505906)
- Testing
- Simultaneous Integrated Boost Technique
- Where
- Netherlands
- Volunteers
- 5,043 people
- Sponsor
- University Medical Center Groningen
Breast Cancer, Colon Cancer
Testing a Spanish Version of a Patient Toxicity Questionnaire
Background: The Common Terminology Criteria for Adverse Events (CTCAE) is a list of toxicities and side effects that may occur when people are having cancer treatment.
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT01517152
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Scleroderma
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
The aim of the study is to compare the exposure to environmental and professional toxics by patients with systemic scleroderma and by patients not achieved by this pathology.
- Trial name
- PRESSY (NCT03262922)
- Where
- France
- Volunteers
- 327 people
- Sponsor
- Rennes University Hospital
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction
- Trial name
- NCT03585946
- Testing
- Site specific standard of care comparison
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients
The purpose of this national, multi-site study is to determine the safety and effectiveness of the Contura catheter in breast cancer patients undergoing accelerated partial breast irradiation.
- Trial name
- NCT00882596
- Testing
- Accelerated partial breast irradiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Center of Irvine
Breast Cancer, Chemotherapeutic Toxicity
Alpha-Lipoic Acid in Breast Cancer Patients
Investigate the ability of alpha lipoic acid to counter act anthracycline associated cardiotoxicity and cumulative taxens-related PN in patients with breast cancer.
- Trial name
- NCT03908528
- Testing
- Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Damanhour University
Breast Cancer Female
Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support
ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum care of women with breast cancer…
- Trial name
- ATOPE-PRO (NCT06518200)
- Testing
- Individualised health recommentations, General health recommendations, Individualised physical exercise program
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Universidad de Granada
Radiotherapy Side Effect, Radiodermatitis
Thermal Imaging to Evaluate Skin Toxicity From Radiotherapy
A significant proportion of patients treated with whole-breast or head and neck radiotherapy will experience skin toxicity, i.e. skin dermatitis, which may lead to erythema, dry desquamation and wet desquamation.
- Trial name
- NCT04013711
- Testing
- Thermography
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Chemotherapeutic Toxicity
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
Anthracycline-paclitaxel sequential combination therapy is the standard regimen for perioperative chemotherapy in breast cancer. The strategy of perioperative chemotherapy is based on breast cancer subtype, i.e.
- Trial name
- NCT05302336
- Testing
- Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer After Breast Conserving Surgery Indicating Postoperative Radiotherapy With Boost
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies.
- Trial name
- NCT01948726
- Testing
- Hypofractionation with simultaneous integrated boost
- Where
- 19 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University Hospital Schleswig-Holstein
Mesenchymal Stromal Cells, Psoriasis
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients
The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis.
- Conditions
- Mesenchymal Stromal Cells, Psoriasis, Drug Effect, Drug Toxicity
- Trial name
- NCT04275024
- Testing
- Calcipotriol ointment, PSORI-CM01 Granule, adipose-derived multipotent mesenchymal stem cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.
- Conditions
- Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum, Sjogren Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT03839069
- Testing
- minor salivary gland transplantation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Stage I Breast Cancer
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02096588
- Testing
- Simvastatin, Doxorubicin/cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response
This is a study aimed at testing a commonly available and inexpensive chemical (hydrogen peroxide) for safety and activity in sensitising large cancerous lumps in the breast to a standard course of radiotherapy in women with…
- Trial name
- NCT02757651
- Testing
- Hydrogen Peroxide
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer
The purpose of this study is to evaluate the rate of early and intermediate toxicity related to the AccuBoost System for delivery of APBI in women with resected, early stage breast cancer.
- Trial name
- NCT01463007
- Testing
- Accelerated partial breast irradiation, Extended Follow up
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jaroslaw Hepel